Patents Examined by M Franco G Salvoza
  • Patent number: 10344057
    Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/oror obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/oror fragment Z.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: July 9, 2019
    Assignees: Deutsches Krebsforschungszentrum, Medigene AG
    Inventors: Florian Sonntag, Juergen Kleinschmidt, Markus Hoerer, Kerstin Pino Tossi
  • Patent number: 10342863
    Abstract: Multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins are multimerized Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp 120) and can used as an HIV vaccine.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: July 9, 2019
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Roland K. Strong, Colin Correnti, Leonidas Stamatatos, Andrew McGuire
  • Patent number: 10322152
    Abstract: The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: June 18, 2019
    Assignee: PSIOXUS THERAPEUTICS LIMITED
    Inventors: Brian Robert Champion, Alice Claire Noel Bromley
  • Patent number: 10308958
    Abstract: Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: June 4, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 10301602
    Abstract: Production of virus occlusion bodies that occlude virions comprising genomes of different species of baculoviruses that can be used to combat insect pests. A method is presented for the production of occlusion derived virions (ODVs) that simultaneously comprise genomes of different baculovirus species, occluded in a viral occlusion body (OB) with the structural and morphological features characteristic of baculoviruses. Mixed genome ODVs and OBs can be produced by co-infecting insect cells or insect hosts using two or more different baculoviruses species. Co-infection may be achieved by simultaneous inoculation of the different baculoviruses or with a time interval between inoculations, which results in different proportions of each species' genomes in the ODVs and OBs that are produced. The produced OBs can be used either directly for preparing an insecticide, or to infect susceptible insects to produce larger quantities of mixed genome ODVs and OBs, also useful for combating pest insects.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: May 28, 2019
    Assignees: UNIVERSIDAD PÚBLICA DE NAVARRA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, INSTITUTO DE ECOLOGÍA, A.C., ASSOCIATION POUR LA RECHERCHE ET LE DEVELOPPEMENT DES METHODES ET PROCESSUS INDUSTRIELS (ARMINES)
    Inventors: Primitivo Caballero Murillo, Inés Beperet Arive, Oihane Simón De Goñi, Trevor Williams, Miguel Lopez-Ferber
  • Patent number: 10294452
    Abstract: The present disclosure provides compositions and methods for extracting viral particles of a recombinant adeno-associated virus (AAV) or an adenovirus (AdV) from a sample comprising cells enclosing the viral particles. The method can include lysing the cells with the addition of an alkaline lysis solution to the sample such that the sample comprises compound(s) buffering pH value about 9.0 to about 11.5 and about 0.1% to about 1% of a detergent precipitating host cell proteins by adding a salting solution to the sample such that the sample comprises about 0.5 M to about 2.0 M of a salt and has a pH of about 4.0 to about 7.0.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: May 21, 2019
    Inventor: Dao-Yao He
  • Patent number: 10294277
    Abstract: The present invention relates to the stabilization of foot-and-mouth disease virus (FMDV) capsids, by specific substitution of amino acids in a specific region of FMDV VP2. The invention provides stabilized FMDV capsids and vaccines against FMD.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: May 21, 2019
    Assignee: The Pirbright Institute
    Inventors: Abhay Kotecha, David Stuart, Elizabeth Fry, Robert Esnouf
  • Patent number: 10286056
    Abstract: High loading of lipophilic pharmacological agents (in particular, lipophilic immunopotentiators) in oil-in-water emulsions can result in crystallisation of the lipophilic agent. To overcome this problem the invention uses an oil-in-water emulsion in combination with a crystallisation inhibitor, and this combination provides emulsions which can be loaded with high levels of lipophilic pharmacological agents.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: May 14, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis Brito, Manmohan Singh, Derek O'Hagan
  • Patent number: 10207009
    Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: February 19, 2019
    Assignees: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSM, BIONTECH RNA PHARMACEUTICALS GMBH
    Inventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz, Lars Koste
  • Patent number: 10209248
    Abstract: The present invention provides an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres). The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: February 19, 2019
    Assignee: Institut Pasteur
    Inventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
  • Patent number: 10201605
    Abstract: The present invention provides an attenuated strain of porcine pseudorabies virus (PRV), in which said attenuated strain of PRV is a variant strain of PRV with inactivation of gI/gE/11K/28K proteins. In addition, the present invention also provides a vaccine composition comprising the attenuated strain of PRV as an antigen, a preparation method and use thereof. Proved by immunogenicity and pathogenicity testing of the live vaccine, said live PRV vaccine can provide a good protection for pigs with no clinical signs observed, indicating excellent immune protection.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: February 12, 2019
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Xuke Zhang, Jinzhong Sun, Feifei Tan
  • Patent number: 10202617
    Abstract: An expression cassette, wherein said expression cassette comprises: (a) an ie 1 promoter from white spot syndrome virus or a variant thereof; (b) a nucleic acid sequence encoding an N-terminal gp64 signal peptide or variant thereof, a nucleic acid sequence encoding an antigenic peptide, a nucleic acid encoding a transmembrane region, and a nucleic acid encoding a gp64 cytoplasmic region or variant thereof; in which the promoter is operably linked to the nucleic acid sequence.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: February 12, 2019
    Assignee: Temasek Life Sciences Laboratory Limited
    Inventors: Premanand Balraj, Hwei-Sing Jimmy Kwang, Anbu Kumar Karuppannan
  • Patent number: 10201602
    Abstract: A live or inactivated recombinant vaccine is described, comprising a viral vector and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, wherein the viral vector is capable of generating a cell immune response due to an increased alpha and/or gamma interferon production, and is capable of a quick replication, and it has inserted a nucleotide sequence of the ORF 5 and ORF 6 from PRSS.
    Type: Grant
    Filed: May 7, 2011
    Date of Patent: February 12, 2019
    Assignee: LABORATORIO AVI-MEX, S.A. DE C.V.
    Inventors: Bernardo Lozano-Dubernard, Ernesto Soto-Priante, David Sarfati-Mizrahi, Jesús Horacio Lara-Puente
  • Patent number: 10197562
    Abstract: The present invention provides an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres). The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 5, 2019
    Assignee: INSTITUT PASTEUR
    Inventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
  • Patent number: 10172935
    Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: January 8, 2019
    Assignee: CureVac AG
    Inventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
  • Patent number: 10174292
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: January 8, 2019
    Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute
    Inventors: Viktoriya Dubrovskaya, Francisco Javier Guenaga, Richard Wyatt
  • Patent number: 10166188
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for vitrifying biological preparations, including peptides, antigens, antibodies, cells, and the like.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: January 1, 2019
    Assignee: MERIAL, INC.
    Inventor: Noel Yves Henri Jean Genin
  • Patent number: 10167333
    Abstract: The invention is in the field of medical treatment and prevention. The invention provides an antibody or a part thereof capable of specifically binding to the Hepatitis B surface antigen (HBsAg) and having Hepatitis B Virus (HBV) neutralizing activity, wherein said antibody or fragment thereof comprises a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO: 5, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO: 6, a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO: 7, a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO: 8, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO: 9 and a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO: 10.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: January 1, 2019
    Inventor: Mario Umberto Francesco Mondelli
  • Patent number: 10155023
    Abstract: The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: December 18, 2018
    Assignee: CALDER BIOSCIENCES INC.
    Inventor: Christopher Patrick Marshall
  • Patent number: 10137186
    Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 27, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga